Starr International Finance AG, a Swiss private equity firm, has agreed to make a $20.5 million investment in Techpool Bio-Pharma Company, a Guangzhou pharmaceutical company that specializes in human urinary protein-based drugs. Starr will purchase 20 million new shares directly from Techpool for $14.6 million, and it will also acquire 8 million shares from Guangzhou Bopu Bio Technology, a Techpool shareholder. After the investment, Starr will own 28% of Techpool, which will become a foreign investment enterprise. More details...